EpiBone

About:

EpiBone is a bone reconstruction company that advances skeletal reconstruction through 3D design and living cells.

Website: http://epibone.com

Twitter/X: GrowYourOwnBone

Top Investors: Tachyon Ventures, Lifespan Vision Ventures, Plum Alley, Covenant Venture Capital, EMV Capital

Description:

EpiBone is a pioneering regenerative medicine company at the forefront of bone and cartilage repair. Leveraging the power of stem cells, biomimicry, and 3D fabrication, they are developing a pipeline of innovative products with enormous potential to revolutionize orthopedic repair. Their lead product, a living, anatomically precise 3D bone graft, completed its Phase I/IIa clinical trial in August 2023. The rest of their pipeline focuses on cartilage repair, and includes an allogeneic osteochondral plug, whose IND was approved in July 2023. Their cartilage portfolio also includes an injectable cartilage filler that was partly funded by the Department of Defense.

Total Funding Amount:

$33.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Jersey City, New Jersey, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)epibone.com

Founders:

Elisa Cimetta, Nina Tandon, Sarindr Bhumiratana

Number of Employees:

11-50

Last Funding Date:

2024-11-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai